Incyte Corporation is set to purchase Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, strengthening its position in hematology. The Incyte Vega Therapeutics acquisition, valued at up to $2 billion, centers on VGA039, an experimental therapy currently in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder.
Under the terms of the Incyte and Vega Therapeutics deal, Incyte will pay $1.25 billion upfront, while Star Therapeutics could receive an additional $750 million if certain sales milestones are achieved.
“This transaction has all of the attributes we look for in business development opportunities,” said Bill Meury, Chief Executive Officer of Incyte.
According to an official announcement, the acquisition is expected to close during the third quarter of 2026, subject to customary regulatory approvals. With investing in bleeding disorder treatment, Incyte aims to expand beyond existing products and invest in late-stage therapies with significant commercial and clinical potential.
What is Inside The Incyte Vega Therapeutics Acquisition?
Incyte Vega Deal to Address Unmet Needs in Von Willebrand Disease
The Incyte Vega Therapeutics acquisition is an opportunity to improve treatment options for patients living with von Willebrand disease.
VWD occurs when the body lacks sufficient amounts of von Willebrand factor, a protein that helps blood clot properly. As a result, patients may experience frequent nosebleeds, prolonged bleeding after injuries, excessive bruising, or heavy menstrual bleeding.
Incyte estimates that approximately 135,000 people in the United States have been diagnosed with the condition.
Current preventive treatments often rely on replacement therapies that require frequent intravenous administration. These repeated treatments can place a significant burden on patients and caregivers.
VGA039 Becomes the Centerpiece of the Deal
The Incyte and Vega Therapeutics deal focuses on VGA039, an investigational monoclonal antibody designed to improve the body’s ability to control bleeding.
The therapy targets Protein S, a naturally occurring protein involved in blood clotting. By modulating Protein S activity, VGA039 aims to enhance hemostasis, the process that stops bleeding after injury.
According to Incyte, VGA039 has the potential to become the first subcutaneous preventive treatment for patients with von Willebrand disease. Unlike current therapies that often require multiple intravenous infusions every week, VGA039 is being developed as a once-monthly self-administered injection.
Meury described VGA039 as a “first-in-class” asset with promising early clinical data and a manageable development pathway.
What Is Happening In The VIVID-6 Study?
The Phase 3 VIVID-6 study is currently evaluating VGA039 in patients across all forms of von Willebrand disease.
The global trial is investigating the safety and effectiveness of the VWD therapy as a preventive treatment to reduce bleeding episodes. The study includes patients with substantial disease burden and aims to determine whether monthly injections can provide sustained bleeding control.
VGA039 has already received several important designations from the U.S. Food and Drug Administration (FDA), including:
- Breakthrough Therapy designation
- Fast Track designation
- Orphan Drug designation
- Rare Pediatric Disease designation
These designations are intended to support the development of therapies targeting serious conditions with limited treatment options.
Why Is The Vega Therapeutics Acquisition Important for Incyte?
The Incyte Vega Therapeutics acquisition is an opportunity for the company to expand future growth drivers within its oncology and hematology expansion strategy.
The acquisition provides Incyte with a late-stage asset as the company prepares for potential revenue pressures later in the decade when the patent for its blockbuster drug Jakafi begins to expire.
According to reports, Jakafi generated approximately $3.09 billion in sales during 2025, making market diversification important for the company.
The acquisition of a Star Therapeutics subsidiary also aligns with Incyte’s stated strategy of focusing on innovative therapies in core therapeutic areas where the company already has deep scientific and commercial expertise.
What A Deal with Incyte Corporation Means for Star Therapeutics?
For Star Therapeutics, the transaction with Incyte represents a significant milestone in the development of one of its most advanced programs.
“This milestone reflects our team’s deep commitment to innovation,” said Adam Rosenthal, Founder and CEO of Star Therapeutics, in the company announcement.
Rosenthal added that Incyte’s global reach and hematology expertise position the company to continue advancing VGA039 toward regulatory approval and commercialization.
As the Incyte and Vega Therapeutics transaction moves toward completion, investors, healthcare professionals, and patient communities will be closely watching the progress of the Phase 3 program and future regulatory developments.
As pharmaceutical mergers and acquisitions continue to shape the future of rare disease treatment, innovative therapies may offer greater convenience and improved outcomes for patients with fewer treatment opportunities.
